Progress of poly (ADP-ribose) polymerase inhibitors in treatment of colorectal cancer

VernacularTitle:聚二磷酸腺苷核糖聚合酶抑制剂治疗结直肠癌的研究进展
Author: Minghan SONG ¹ ; Lijuan SHAO ; Size CHEN
Author Information

1. 广东药科大学附属第一医院肿瘤免疫科，广州　510080
Keywords: Colorectal neoplasms; Poly (ADP-ribose) polymerase inhibitors; Homologous recombination deficiency; Treatment outcome
From: Cancer Research and Clinic 2024;36(2):153-156
CountryChina
Language:Chinese
Abstract: Colorectal cancer is a highly malignant disease characterized by a poor prognosis. Although the targeted therapy based on chemotherapy improves the efficacy, the prognosis of advanced colorectal cancer patients is poor. Poly (ADP-ribose) polymerase (PARP) inhibitors, which act through a synergistic lethal mechanism, have been widely utilized in treating ovarian and breast cancer cases with homologous recombination deficiency and have demonstrated positive clinical outcomes. Recently, due to advancements in next-generation sequencing technology and the development of precision targeted therapy, an increasing number of clinical trials have started to investigate the potential of PARP inhibitors in colorectal cancer treatment. This review summarized the molecular mechanism of PARP inhibitors in the treatment of colorectal cancer and the application of several combined PARP inhibitors therapy regimens in colorectal cancer, in order to provide new insights for the treatment of colorectal cancer.